` ALACT (Acticor Biotech SA) vs DAX Index Comparison - Alpha Spread

A
ALACT
vs
D
DAX Index

Over the past 12 months, ALACT has underperformed DAX Index, delivering a return of 0% compared to the DAX Index's +18% growth.

Stocks Performance
ALACT vs DAX Index

Loading
ALACT
DAX Index
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
ALACT vs DAX Index

Performance Gap Between ALACT and GDAXI
HIDDEN
Show

Performance By Year
ALACT vs DAX Index

Loading
ALACT
DAX Index
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Acticor Biotech SA vs Peers

DAX Index
ALACT
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Acticor Biotech SA
Glance View

Market Cap
3.9m EUR
Industry
Biotechnology

Acticor Biotech SAS engages in the research and development of an antithrombotic agent for the treatment of the acute thrombotic diseases. The company is headquartered in Paris, Ile-De-France and currently employs 22 full-time employees. The company went IPO on 2021-11-01. The firm is a clinical stage biopharmaceutical company, a spin-off from INSERM (French National Institute of Health and Medical Research), specialized in the research and development of medicines for the treatment of thrombotic diseases, in particular acute ischemic strokes and pulmonary embolisms. The group has one product in Phase II clinical development (Glenzocimab) and its products in pipeline are ACTIMIS, GARDEN, ACTISAVE and GREEN. Its partnering companies are Ouest Valorisation, Genopole, Medicine and Inserm.

ALACT Intrinsic Value
Not Available
Back to Top